PUBLIC COMPANY
save$BMRNBIOMARIN PHARMACEUTICAL INC
$BMRN59.87+0.69%Novato, CA, USupdated 1d ago
community read0 votes
pipeline
7
marketed
6
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(7)
pipeline depth7 products
1Phase 36Marketed
Marketed
cerliponase alfa
Batten Disease
Marketedelosulfase alfa
Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome )
Marketedgalsulfase
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome )
Marketedpegvaliase
Hyperphenylalaninemia
Marketedvaloctocogene roxaparvovec
Hemophilia A (Factor VIII Deficiency)
Marketedvosoritide
Noonan Syndrome
Atrial natriuretic peptide receptor 2
Phase 3efmirenpase alfa
Arterial Calcification
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase3Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
- phase3Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
- phase2Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
- —Cerliponase Alfa Observational Study in the US
- phase2A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
- phase2A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
- phase4Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
- phase2A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
🐶 Hiring Signal
News
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 7h ago
- Novo, BioMarin, Enanta dole out pink slipsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Teva claims success in celiac study; BioMarin, Ascendis settle patent disputeTeva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.biopharma_dive · 28d ago
- Biomarin nabs big royalties in achondroplasia patent settlement with AscendisBiomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…biospace · 1mo ago
- 7 biopharma M&A deals where layoffs followedWorkforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…biospace · 1mo ago
- BioMarin acquires experimental drug for rare bone disorder in $275M dealThe Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.biopharma_dive · 1mo ago
- BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZenecaBioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.fiercebiotech · 1mo ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 1mo ago
- BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indicationBioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.biospace · 1mo ago
- BioMarin axes $270M rare disease asset after missing phase 3 endpointBioMarin Pharmaceutical has ended development of BMN 401 in all indications months after reporting mixed phase 3 data on the rare disease prospect.fiercebiotech · 1mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that